Only logged in users can watch the content

Chat keyboard_arrow_down
Description keyboard_arrow_down
Minimally Invasive treatment for BPH; Water steam generated by radiofrequency; Transmitted via convection throughout the targeted zone of the prostate over 9 seconds.

Technique description:

  • Minimally Invasive treatment for BPH
  • Water steam generated by radiofrequency
  • Transmitted via convection throughout the targeted zone of the prostate over 9 seconds
  • Targeted, controlled dose of thermal energy (steam) causes instant cell death and an ablation field
  • Overlapping ablation zones open up the obstructing prostate tissue over the subsequent 3 months


Procedure Steps:

  • 1. Baseline history, physical, cystoscopy, prostate volume assessment by imaging as preparation before day of treatment
  • 2. Prepare and prime hand-piece. Small amount of lubrication
  • 3. Gentle, atraumatic insertion of the hand-piece
  • 4. Assess prostate length and presence of median lobe while entering
  • 5. Begin 1cm back from bladder neck (2 fields of view) for first injection
  • 6. Continue moving back 1cm at a time (2 fields of view) targeting the bulkiest part of the lateral lobe
  • 7. Stop at apical tissue/verumontanum
  • 8. Repeat steps 5 & 6 on contralateral lobe
  • 9. If median lobe or central zone hypertrophy, treat 1cm back from crest of the lobe. Multiple steam injections may be required
  • 10. Remove scope and insert Foley catheter


Learning Points:

  • Know prostate volume ahead of time
  • Be gentle when Inserting the hand-piece to avoid trauma
  • Start 1cm back from bladder neck and inject laterally in 1cm (2 field of view) Increments
  • Inject steam into the bulkiest part of the prostate, waiting 2 additional seconds (after the 9 second dose of steam) before retracting the needle
  • Treat both lateral lobes followed by treating the median lobe or central zone as required


Clinical History:

  • Case1: 67M, BPH 20 yrs, Prostate Volume 50 cc, IPSS 23/4, Qmax 8ml/sec, PVR 43mL, Meds: Doxazosin and Dutasteride
  • Case 2: 63M, Prostate Volume 64cc, Urinary retention
  • Case 3: 51M, Prostate Volume 49cc, IPSS 24/5, Qmax 3ml/sec, PVR 156mL, Meds tamsulosin
  • Case 4: 67M, Prostate Volume 59cc, IPSS 24/4, Qmax 6mL/sec, PVR 59mL, Meds Silodosin
Faculty keyboard_arrow_down
Dr. Dean Elterman MD, MSc, FRCSC, Associate Professor of Urology, University of Toronto; Fellowship Director, Functional Urology and Staff Urologist, Toronto Western Hospital, University Health Network, Chief Medical Officer, MedTech Syndicates, Canada Urology
Related Content keyboard_arrow_down